medigraphic.com
ISSN 1527-3172 (Digital)

2011, Número 2

<< Anterior Siguiente >>

MEDICC Review 2011; 13 (2)


Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba

Aragonés C, Sánchez L, Campos JR, Pérez J

Idioma: Ingles.
Referencias bibliográficas: 57
Paginas: 17-23
Archivo PDF: 264.73 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. UNAIDS. AIDS epidemic update 2009 [Internet]. 2009 Nov [cited 2010 Jan 19]. Available from: http://data.unaids.org/pub/Report/2009/jc1700_ epi_update_2009_en.pdf.

  2. Estruch L, Santín M, Lantero MI, Ochoa R, Joanes J, Alé K, et al. República de Cuba. Informe nacional sobre los progresos realizados en la aplicación del UNGASS. La Habana [Internet]. Geneva: UNAIDS; 2010 Mar [cited 2010 June 20]. 42 p. Available from: http://data.unaids.org/ pub/Report/2010/cuba_2010_country_progress_ report_es.pdf. Spanish.

  3. Pérez J, Pérez D, González I, Díaz Jidy M, Orta M, Aragonés C, et al. Approaches to the Management of HIV/AIDS in Cuba. Geneva: World Health Organization; 2004.

  4. Aragonés López C, Campos Díaz JR, Sánchez Valdés L, Pérez Avila LJ. Grupos de Prevención del SIDA (GPSIDA): 15 años de trabajo sostenido en la prevención del VIH/SIDA. Rev Cubana Med Trop. 2007;59(3):261–9. Spanish.

  5. Bayer R, Healton C. Controlling AIDS in Cuba. The logic of quarantine. N Engl J Med. 1989 Apr 13;320(15):1022–4.

  6. Pérez-Stable EJ. Cuba’s response to the HIV epidemic. Am J Public Health. 1991 May;81(5):563–7.

  7. Scheper-Hughes N. AIDS, public health, and human rights in Cuba. Lancet. 1993 Oct 16;342(8877):965–7.

  8. Pérez Ávila LJ, Pérez Correa DF, Orta Gutiérrez M, Martínez Rodríguez A, Luzardo C, Aragonés López C, et al. Tratamiento antirretroviral de alta efi ciencia en pacientes cubanos con genéricos de producción nacional. II Foro en VIH/SIDA/ITS en América Latina y el Caribe. 2003 Apr 7–12; Havana, Cuba [Internet]. Havana: Pedro Kourí Institute of Tropical Medicine (CU); 2003 [cited 2011 Feb 1]. 12 p. Available from: http://www. foro2003.sld.cu/recursos/ver.php/Pérez%20 Avila?id=1065. Spanish.

  9. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patientreported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 Jun 18;13(9):1099–107.

  10. Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13 Suppl A:S271–8.

  11. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000 Jun;30 Suppl 2:S171–6. Review.

  12. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003 Apr;17(4):169–77.

  13. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV–1 viral load, and development of drug resistance in an indigent population. AIDS. 2000 Mar 10;14(4):357–66.

  14. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999 May;14(5):267–73.

  15. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004 May;53(5):696–9.

  16. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001 Jun 15;15(9):1181–3.

  17. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defi c Syndr. 2002 May 1;30(1):105–10.

  18. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997 Nov 15;11(14):1665–70.

  19. Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care. 2004 May;16(4):471–84.

  20. Cahn P, Vibhagool A, Schechter M, Soto- Ramirez L, Carosi G, Smaill F, et al. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/ zidovudine. Curr Med Res Opin. 2004 Jul;20(7):1115–23.

  21. Castro A. Adherence to Antiretroviral Therapy: Merging the Clinical and Social Course of AIDS. PLoS Med. 2005 Oct 4;2(12):e338.

  22. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patientand provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001 Dec;54 Suppl 1:S91–8.

  23. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defi c Syndr. 2001 Apr 15;26(5):435–42.

  24. Nemes MIB, Carvalho HB, Souza MFM. Antiretroviral therapy adherence in Brazil. AIDS. 2004;18 Suppl 3:S15–20.

  25. Weiss JJ. Attitudinal factors and adherence to protease inhibitor combination therapy. In: Aggleton P, Moatti JP, Prieur A, Sandfort T, Souteyrand Y, editors. AIDS in Europe–New Challenges for the Social Sciences. United Kingdom: Routledge; 2000. p. 45–56.

  26. Moatti JP, Spire B. Living with HIV/AIDS and adherence to antiretroviral treatments. In: Aggleton P, Moatti JP, Prieur A, Sandfort T, Souteyrand Y, editors. AIDS in Europe– New Challenges for the Social Sciences. United Kingdom: Routledge; 2000. p. 57–73.

  27. Abell N, Lewis S, Immel M. Adherence Attitude Inventory. The Body: the complete HIV/AIDS Resource [Internet]. 2004 Aug [updated 2004 Aug 16; cited 2005 January 20]. Available from: http:// www.thebody.com/aacm/aai_survey.html.

  28. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to Medication Treatment: A Qualitative Study of Facilitators and Barriers Among a Diverse Sample of HIV+ Men and Women in four US Cities. AIDS Behav. 2003 Mar;7(1):61–72.

  29. Sigma Research [Internet]. London: Stigma Research Anderson; c2011. The impact of combination therapy on the lives of people with HIV–a pilot study; 1999 [cited 2004 October 21];[about 1 screen]. Available from: http://www.sigmaresearch. org.uk/go.php?/projects/project01/.

  30. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR, et al. Barriers to HAART Adherence Among Human Immunodefi ciency Virus-Infected Adolescents. Arch Pediatr Adolesc Med. 2003 Mar;157(3):249–55.

  31. Race K, Wakeford E. Dosing on time: developing adherent practice with highly active anti-retroviral therapy. Cult Health Sex. 2000;2(2):213–28.

  32. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000 Jun;50(11):1599–605.

  33. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials. 2000 Jul–Aug;1(1):36–46.

  34. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, et al. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defi c Syndr. 2005 Nov 1;40(3):301–6.

  35. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIVinfected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005 Jan;17(1):10–22.

  36. Cederfjäll C, Langius-Eklöf A, Lidman K, Wredling R. Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. AIDS Patient Care STDS. 2002 Dec;16(12):609–16.

  37. Li L, Lee SJ, Wen Y, Lin C, Wan D, Jiraphongsa C. Antiretroviral therapy adherence among patients living with HIV/AIDS in Thailand. Nurs Health Sci. 2010 Jun;12(2):212–20.

  38. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons; 1989.

  39. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of selfreported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defi c Syndr. 2000 Apr 15;23(5):386–95.

  40. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000 Jun;12(3):255–66.

  41. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002 May;54(10):1481–96.

  42. Bonolo P de F, Cesar CC, Acúrcio FA, Ceccato MG, de Pádua CA, Alvares J, et al. Nonadherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005 Oct;19 Suppl 4:S5–13.

  43. Pinheiro CA, de-Carvalho-Leite JC, Drachler ML, Silveira VL. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. Braz J Med Biol Res. 2002 Oct;35(10):1173–81.

  44. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002 Feb 15;16(3):369–79.

  45. Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, et al. Health-Related Quality of Life After 1 Year of Highly Active Antiretroviral Therapy. J Acquir Immune Defi c Syndr. 2003 Jan 1;32(1):38–47.

  46. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: Results From the French National APROCO cohort. J Acquir Immune Defi c Syndr. 2001 Nov 1;28(3):232–9.

  47. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L, et al. Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007 Jul;21 Suppl 3:S73–8.

  48. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defi c Syndr. 2003 Nov 1;34(3):281–8.

  49. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to Antiretroviral Therapy in HIV-Infected Patients Attending a Public, Urban Clinic in Kampala, Uganda. Clin Infect Dis. 2006 Jan 15;42(2):252–9.

  50. Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM, Sethi AK. Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic). 2009 Mar– Apr;8(2):139–47.

  51. Collazos J, Asensib V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS. 2007 Apr 23;21(7):835–43.

  52. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21–30.

  53. Malta M, Petersen ML, Clair S, Freitas F, Bastos FI. Adherence to antiretroviral therapy: a qualitative study with physicians from Rio de Janeiro, Brazil. Cad Saude Publica. 2005 Sep- Oct;21(5):1424–32.

  54. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defi c Syndr. 2001 Jan 1;26(1):82–92.

  55. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000 Mar;19(2):124–33.

  56. Woods SP, Dawson MS, Weber E, Gibson S, Grant I, Atkinson JH, et al. Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009 Jan;15(1):42–52.

  57. Marco A, Knobel H, Guelar A. La adhesión al tratamiento antirretroviral; una perspectiva global del problema y posibles soluciones. Enf Emerg. 2000;2(1):45–53. Spanish.




2020     |     www.medigraphic.com